Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3
RCKT Stock | USD 11.43 0.13 1.12% |
Slightly above 67% of Rocket Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Rocket Pharmaceuticals suggests that many traders are alarmed. Rocket Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Rocket Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Rocket |
Filed transaction by Rocket Pharmaceuticals Officer See Remarks. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Rocket Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Rocket Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Rocket Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rocket Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rocket Pharmaceuticals Fundamental Analysis
We analyze Rocket Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Rocket Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Rocket Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rocket Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Rocket Pharmaceuticals Related Equities
STRO | Sutro Biopharma | 3.21 | ||||
SLDB | Solid Biosciences | 1.95 | ||||
SNDX | Syndax Pharmaceuticals | 1.76 | ||||
MGTX | MeiraGTx Holdings | 1.31 | ||||
REPL | Replimune | 1.30 | ||||
RVMD | Revolution Medicines | 1.05 | ||||
MIRM | Mirum Pharmaceuticals | 1.05 | ||||
PLRX | Pliant Therapeutics | 0.98 | ||||
PCVX | Vaxcyte | 0.64 | ||||
RGNX | Regenxbio | 0.27 | ||||
DYN | Dyne Therapeutics | 0.25 | ||||
MRUS | Merus BV | 0.09 | ||||
DAWN | Day One | 0.16 | ||||
RYTM | Rhythm Pharmaceuticals | 0.34 | ||||
QURE | Uniqure NV | 0.46 | ||||
STOK | Stoke Therapeutics | 0.60 | ||||
CYTK | Cytokinetics | 0.86 | ||||
LRMR | Larimar Therapeutics | 1.25 | ||||
VRDN | Viridian Therapeutics | 1.83 | ||||
INZY | Inozyme Pharma | 2.66 |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.